Short Interest in BioRestorative Therapies, Inc. (NASDAQ:BRTX) Rises By 2,211.5%

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 1,870,000 shares, a growth of 2,211.5% from the May 31st total of 80,900 shares. Based on an average daily volume of 2,110,000 shares, the short-interest ratio is currently 0.9 days. Approximately 34.0% of the company’s shares are sold short.

BioRestorative Therapies Trading Up 10.9 %

BioRestorative Therapies stock opened at $2.03 on Friday. The firm has a 50-day moving average of $1.48 and a 200-day moving average of $1.53. The firm has a market cap of $13.74 million, a P/E ratio of -0.88 and a beta of 61.71. BioRestorative Therapies has a 1-year low of $1.03 and a 1-year high of $4.60.

BioRestorative Therapies (NASDAQ:BRTX) last posted its earnings results on Tuesday, June 11th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.03 million. BioRestorative Therapies had a negative return on equity of 96.09% and a negative net margin of 7,303.33%. Research analysts forecast that BioRestorative Therapies will post -2.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Roth Mkm reiterated a “buy” rating and set a $15.00 target price on shares of BioRestorative Therapies in a report on Wednesday, June 12th.

Institutional Trading of BioRestorative Therapies

A hedge fund recently bought a new stake in BioRestorative Therapies stock. StoneX Group Inc. acquired a new position in BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned 0.51% of BioRestorative Therapies at the end of the most recent reporting period. 69.38% of the stock is currently owned by institutional investors and hedge funds.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.